Feeds:
Posts
Comments

Archive for the ‘LPBI Group, e-Scientific Media, DFP, R&D-M3DP, R&D-Drug Discovery, US Patents: SOPs and Team Management’ Category


In Data Science, A Pioneer Practitioner’s Portfolio of Algorithm-based Decision Support Systems for Operations Management in Several Industrial Verticals: Analytics Designer, Aviva Lev-Ari, PhD, RN

An overview of Data Science as a discipline is presented in

Data Science & Analytics: What do Data Scientists Do in 2020 and a Pioneer Practitioner’s Portfolio of Algorithm-based Decision Support Systems for Operations Management in Several Industrial Verticals

 

On this landscape about IT, The Internet, Analytics, Statistics, Big Data, Data Science and Artificial Intelligence, I am to tell stories on my own pioneering work in data science, Algorithm-based decision support systems design for different organizations in several sectors of the US economy:

Images on 12/7/2019

  • Startups:
  1. TimeØ Group – The leader in Digital Marketplaces Design
  2. Concept Five Technologies, Inc. – Commercialization of DoD funded technologies
  3. MDSS, Inc. – SAAS in Analytical Services
  4. LPBI Group – Pharmaceutical & Media
  • Top Tier Management Consulting: SRI International, Monitor Group;
  • OEM: Amdahl Corporation;
  • Top 6th System Integrator: Perot System Corporation;
  • FFRDC: MITRE Corporation.
  • Publishing industry: was Director of Research at McGraw-Hill/CTB.
  • Northeastern University, Researcher on Cardiovascular Pharmacotherapy at Bouve College of Health Sciences (Independent research guided by Professor of Pharmacology)

Type of institutions:

  • For-Profit corporations: Amdahl Corp, PSC, McGraw-Hill
  • For-Profit Top Tier Consulting: Monitor Company, Now Deloitte
  • Not-for-Profit Top Tier Consulting: SRI International
  • FFRDC: MITRE
  • Pharmaceutical & Media Start up in eScientific Publishing: LPBI Group:
  1. Developers of Curation methodology for e-Articles [N = 5,700],
  2. Developers of electronic Table of Contents for e-Books in Medicine [N = 16, https://lnkd.in/ekWGNqA] and
  3. Developers of Methodologies for real time press coverage and production of e-Proceedings of Biotech Conferences [N = 70].

 

Autobiographical Annotations: Tribute to My Professors

 

Pioneering implementations of analytics to business decision making: contributions to domain knowledge conceptualization, research design, methodology development, data modeling and statistical data analysis: Aviva Lev-Ari, UCB, PhD’83; HUJI MA’76

https://pharmaceuticalintelligence.com/2018/05/28/pioneering-implementations-of-analytics-to-business-decision-making-contributions-to-domain-knowledge-conceptualization-research-design-methodology-development-data-modeling-and-statistical-data-a/

Recollections of Years at UC, Berkeley, Part 1 and Part 2

  • Recollections: Part 1 – My days at Berkeley, 9/1978 – 12/1983 – About my doctoral advisor, Allan Pred, other professors and other peers

https://pharmaceuticalintelligence.com/2018/03/15/recollections-my-days-at-berkeley-9-1978-12-1983-about-my-doctoral-advisor-allan-pred-other-professors-and-other-peer/

  • Recollections: Part 2 – “While Rolling” is preceded by “While Enrolling” Autobiographical Alumna Recollections of Berkeley – Aviva Lev-Ari, PhD’83

https://pharmaceuticalintelligence.com/2018/05/24/recollections-part-2-while-rolling-is-preceded-by-while-enrolling-autobiographical-alumna-recollections-of-berkeley-aviva-lev-ari-phd83/

Accomplishments

The Digital Age Gave Rise to New Definitions – New Benchmarks were born on the World Wide Web for the Intangible Asset of Firm’s Reputation: Pay a Premium for buying e-Reputation

For @AVIVA1950, Founder, LPBI Group @pharma_BI: Twitter Analytics [Engagement Rate, Link Clicks, Retweets, Likes, Replies] & Tweet Highlights [Tweets, Impressions, Profile Visits, Mentions, New Followers] https://analytics.twitter.com/user/AVIVA1950/tweets

Thriving at the Survival Calls during Careers in the Digital Age – An AGE like no Other, also known as, DIGITAL

Professional Self Re-Invention: From Academia to Industry – Opportunities for PhDs in the Business Sector of the Economy

Reflections on a Four-phase Career: Aviva Lev-Ari, PhD, RNMarch 2018

Was prepared for publication in American Friends of the Hebrew University (AFHU), May 2018 Newsletter, Hebrew University’s HUJI Alumni Spotlight Section.

Aviva Lev-Ari’s profile was up on 5/3/2018 on AFHU website under the Alumni Spotlight at https://www.afhu.org/

On 5/11/2018, Excerpts were Published in AFHU e-news.

https://us10.campaign-archive.com/?u=5c25136c60d4dfc4d3bb36eee&id=757c5c3aae&e=d09d2b8d72

https://www.afhu.org/2018/05/03/aviva-lev-ari/

 

Read Full Post »


Tweets and Retweets by @pharma_BI and @AVIVA1950 for #NEVS at 2019 New England Venture Summit, December 4, 2019 at the Hilton in Boston, Dedham, MA, hosted by youngStartUp #NEVS

 

Event Agenda

https://pharmaceuticalintelligence.com/2019/07/23/2019-new-england-venture-summit-december-4th-2019-at-the-hilton-in-boston-dedham-ma-hosted-by-youngstartup-nevs/

liked your Tweet

#NEVS19 @pharma_BI @AVIVA1950 #AI strategic investment high tech ventures are long term for VC and founders milestones entrepreneurs need to meet for BC To accept valuation board controlled by Entrepreneur or by VCs convertible 15% discount negotiation power at product stage vary pic.twitter.com/WxNuRMGn8l

liked your Tweet

We are in the Cloud only #NEVS19 @AVIVA1950 @pharma_BI twitter.com/stevesherlock/

liked your Tweet

#NEVS19 #pharma_BI @AVIVA1950 Mediktor is SAAS B2B in 12 languages need $5-$15M access to Health Care pic.twitter.com/RadPqiAZj6

liked 18 of your Tweets

#NEVS19 @pharma_BI @AVIVA1950 Asymmetrex stem cell counter service model need to establish cell culture lab improve SW automation establish ASTM standard achieve FDA guidance pic.twitter.com/z14Yes3tL9

Show all

liked your Tweet

#NEVS19 @pharma_BI @AVIVA1950 #VC #Investors are presenting the #pulse #investment #market #institutionalInvestors #Ecits #IPO by #M&A #women #leaders #platform #investment #corporate #technology #gamechanging #Entrepreneur #raisingfunds 12-18 month #economic #downturn #deals pic.twitter.com/fFdOQphhsd

Aviva Lev-Ari
@AVIVA1950

Great panel over 120 years of #investment #experience guiding young #entrepreneurs #NEVS19@pharma_BI

Quote Tweet
Gayatri Sarkar 

🌴

🌏

⌛️

@GS_VCactivist
·
I had such a great time talking about “Art of Negotiating Termsheets” with @XFactorVentures @AMD ventures @goodaicapital Millenium Technology Value Partner and @NexusVP at #NEVS19

Image

Image

Image

Aviva Lev-Ari
@AVIVA1950

#NEVS19

who are the customers vs focus on technology and products great technology can fail because management is not aligned technologies can not get traction due to slow adoption in the market optimized valuation take partners long term cost structure

Image

James L. Sherley
@asymmetrex

Asymmetrex at the New England Venture Summit today in Boston(#NEVS19). A featured Life Sciences presenter for stem cell counting.
James L. Sherley, M.D., Ph.D. on LinkedIn: #NEVS19
Asymmetrex at the New England Venture Summit today in Boston(#NEVS19). A featured Life Sciences presenter for stem cell counting….
linkedin.com
1
2

Vivonics Inc.
@VivonicsInc

Vivonics / CranioSense CEO Gordon Hirschman at the #NEVS19 New England Venture Summit, seeking investment for IPASS, our medical device for non-invasive assessment of intracranial pressure (ICP), critical in traumatic brain injury (TBI), stroke and other brain conditions.

Image

1
3

Medigate
@MedigateLtd

Jonathan Langer, CEO of

, spoke with

to share his predictions for #IoT trends in 2020. Read the article here: tek.io/35zIUiC. #cybersecurity

Image

1
10
18

Aviva Lev-Ari
@AVIVA1950

#NEVS19

#AI strategic investment high tech ventures are long term for VC and founders milestones entrepreneurs need to meet for BC To accept valuation board controlled by Entrepreneur or by VCs convertible 15% discount negotiation power at product stage vary

Image

1
2

Aviva Lev-Ari
@AVIVA1950

#NEVS19

spin off @BOSTONUniversity microscopy based ExoBiew #exsosome cell communication Luminex is competitor companion diagnostics liquid Biopsy pancreatic cancer @ BIDMC interrogate exosome for therapeutics another exosome sold for $330M

Image

Aviva Lev-Ari
@AVIVA1950

Quote Tweet
Steve Sherlock
@SteveSherlock
·
Session on angel investing, interesting insights e.g. be transparent! #nevs19 #startups #pitchdeck

Image

Aviva Lev-Ari
@AVIVA1950

#NEVS19

who are the customers vs focus on technology and products great technology can fail because management is not aligned technologies can not get traction due to slow adoption in the market optimized valuation take partners long term cost structure

Image

Aviva Lev-Ari
@AVIVA1950

#NEVS19

SIG.NUM SIG.RHYTHM SIG.12-LED #ECG alternative technology to 12 leads a pad with sensors

Image

Aviva Lev-Ari
@AVIVA1950

#NEVS19

spin off @BOSTONUniversity microscopy based ExoBiew #exsosome cell communication Luminex is competitor companion diagnostics liquid Biopsy pancreatic cancer @ BIDMC interrogate exosome for therapeutics another exosome sold for $330M

Image

1
1

Aviva Lev-Ari
@AVIVA1950

#NEVS19

@ABIVA1950

MICROSCOPY INDUSTRY Microdissection market life science research platform open platform for Re-agent companies Cartridge removable Live Cell imaging market need $5M

Image

1
1

Aviva Lev-Ari
@AVIVA1950

#NEVS19

micro needles for diagnostics using ISF #Interstitial System Fluid uses #glucose, #allergy, #neonatal

Image

Aviva Lev-Ari
@AVIVA1950

#NEVS19

Asymmetrex stem cell counter service model need to establish cell culture lab improve SW automation establish ASTM standard achieve FDA guidance

Image

1

Aviva Lev-Ari
@AVIVA1950

#NEVS19

FIRST LIGHT DIAGNOSTICS antibiotics resistance C-Diff MRSA Rapid AST Anti microbial susceptibility Testing B Round pre Revenue small valuation

Image

1

Aviva Lev-Ari
@AVIVA1950

#NEVS19

A DOWN TURN HURTS MOST INVESTORS FUND RAISERS don’t go for the biggest valuation if not meet numbers second trench negatively affected same for valuation technology progresses support Series A, B

1

1

Aviva Lev-Ari
@AVIVA1950

#NEVS19

device requires less energy than LVAD no support continuous mode pulsitile mode Euro16M needed to complete animal trials

Image

1

Aviva Lev-Ari

Aviva Lev-Ari
@AVIVA1950

Quote Tweet
Steve Sherlock
@SteveSherlock
·
Quote “I never invest in part time founders” and “If you can’t commit full time you shouldn’t be raising money” #startups #vc #angel #nevs19

Aviva Lev-Ari
@AVIVA1950

#NEVS19

micro needles for diagnostics using ISF #Interstitial System Fluid uses #glucose, #allergy, #neonatal

Image

1

Aviva Lev-Ari
@AVIVA1950

#NEVS19

device requires less energy than LVAD no support continuous mode pulsitile mode Euro16M needed to complete animal trials

Image

1

Aviva Lev-Ari
@AVIVA1950

Quote Tweet
Steve Sherlock
@SteveSherlock
·
Quote “I never invest in part time founders” and “If you can’t commit full time you shouldn’t be raising money” #startups #vc #angel #nevs19

Aviva Lev-Ari
@AVIVA1950

#NEVS19

A DOWN TURN HURTS MOST INVESTORS FUND RAISERS don’t go for the biggest valuation if not meet numbers second trench negatively affected same for valuation technology progresses support Series A, B

1

Aviva Lev-Ari
@AVIVA1950

Image

2

Aviva Lev-Ari
@AVIVA1950

#NEVS19

A DOWN TURN HURTS MOST INVESTORS FUND RAISERS don’t go for the biggest valuation if not meet numbers second trench negatively affected same for valuation technology progresses support Series A, B

1

Aviva Lev-Ari
@AVIVA1950

#NEVS19

SIG.NUM SIG.RHYTHM SIG.12-LED #ECG alternative technology to 12 leads a pad with sensors

Image

Read Full Post »


Data Science & Analytics: What do Data Scientists Do in 2020 and a Pioneer Practitioner’s Portfolio of Algorithm-based Decision Support Systems for Operations Management in Several Industrial Verticals

Curator: Aviva Lev-Ari, PhD, RN

Based on  Jesse Anderson’s work on data teams Kathleen Walch in Why Data Scientists Aren’t Data Engineers makes several keen distinctions between the two skill sets.

I can attest that she is absolutely correct. See below, a Pioneer Practitioner’s Portfolio of Algorithm-based Decision Support Systems for Operations Management in Several Industrial Verticals

 

These key distinctions are:

Data Scientists vs Data Engineers

In the mid-2000s, we saw the emergence of the Data Scientist position. As cited in the O’Reilly article: “This increase in the demand for data scientists has been driven by the success of the major Internet companies. Google, Facebook, LinkedIn, and Amazon have all made their marks by using data creatively: not just warehousing data, but turning it into something of value.” Not surprisingly, any organization that has data of value is looking at data science and data scientists to increasingly extract more value from that information.

Originating from roots in statistical modeling and data analysis, data scientists have backgrounds in advanced math and statistics, advanced analytics, and increasingly machine learning / AI.  The focus of data scientists is, unsurprisingly, data science — that is to say, how to extract useful information from a sea of data, and how to translate business and scientific informational needs into the language of information and math. Data scientists need to be masters of statistics, probability, mathematics, and algorithms that help to glean useful insights from huge piles of information. These data scientists usually have learned programming out of necessity more than anything else in order to run programs and run advanced analysis on data.  As a result, the code that data scientists have usually been tasked to write, is of a minimal nature – only as necessary to accomplish a data science task (R is a common language for them to use) and work best when they are provided clean data to run advanced analytics on. A data scientist is a scientist who creates hypothesis, runs tests and analysis of the data, and then translates their results for someone else in the organization to easily view and understand.

On the other hand, data scientists can’t perform their jobs without access to large volumes of clean data. Extracting, cleaning, and moving data is not really the role of a data scientist, but rather that of a data engineer. Data Engineers have programming and technology expertise, and have previously been involved with data integration, middleware, analytics, business data portal, and extract-transform-load (ETL) operations. The data engineer’s center of gravity and skills are focused around big data and distributed systems, and experience with programming languages such as Java, Python, Scala, and scripting tools and techniques.  Data engineers are challenged with the task of taking data from a wide range of systems in structured and unstructured formats, and data which is usually not “clean”, with missing fields, mismatched data types, and other data-related issues. These data engineers need to use their programming, integration, architecture, and systems skills to clean all the data and put it into a format and system that data scientists can then use to analyze, build their data models, and provide value to the organization. In this way, the role of a data engineer is an engineer who designs, builds and arranges data.

Can there be a combined Data Scientist-Engineer role?

While it might seem that the roles of a data scientist and data engineer are distinct, data scientists and data engineers share many traits and skill sets. These overlapping skills include the necessity to work with and manipulate big data sets, programming skills to apply operations to the data, data analytics skills, and general fluency with systems operations.

Rather than engineering and programming-centric tools, data scientists need data science-centric tools. Right now there’s a growing collection of these tools, often emerging from data or predictive analytics environments that suit the needs of data scientists. However, it’s possible that even more business-centric tools might be appropriate, especially as the data scientists become more embedded with the line of business. For example, decades ago if you wanted to operate on large volumes of data in a spreadsheet-like format, this involved programming, but tools like Excel introduced things like pivot tables and now business managers are able to perform all sorts of analyses. It’s only a matter of time before tools like Excel embed data science capabilities, or business-centric data mining and analysis tools into their products.

As the talent gap for data scientists continues to widen, there is no doubt that we will see new tools created out of necessity to allow non-technical (read: business) people to run, test, and analyze data. Strategic business managers will begin to learn data science, without needing or wanting programming or data integration experience.  Traditional data scientists will still be needed to run very complex analysis of data. For the most part however, basic analysis will move more to the business unit due to increasingly easy-to-use tools. This means we have still yet to see which tool or technology will be the dominant one for ML and data science in the enterprise.

 

 

My SOURCES for the evolution of the field of Data Science are the following:

 Jesse Anderson’s work on data teams

Learn How to Create and Manage Big Data Teams

This Free, 73 Page E-Book is the Complete Guide to Successful Big Data projects

I’m really tired of seeing Big Data projects fail. They fail for both technical and managerial reasons. They all fail for similar reasons and that’s just sad because we can fix or prevent them. Gartner’s research shows that 85% of Big Data projects don’t even make it into production.

“Only 15 percent of businesses reported deploying their big data project to production, effectively unchanged from last year (14 percent).”

October 4, 2016 Gartner Press Release

https://www.bigdatainstitute.io/data-engineering-teams-book/

 

December, 1, 2019, 9:48 am

Why Data Scientists Aren’t Data Engineers

Kathleen Walch

Managing Partner & Principal Analyst at AI Focused Research and Advisory firm Cognilytica

https://www.forbes.com/sites/cognitiveworld/2019/12/01/why-data-scientists-arent-data-engineers/amp/?__twitter_impression=true

 

Translating Between Computer Science and Statistics

Posted on December 1, 2019

Gil Press

https://whatsthebigdata.com/2019/12/01/translating-between-computer-science-and-statistics/

 

Jan 8, 2019, 06:18am

The AI Chronicles: Combining Statistical Analysis And Computing From Hollerith To Zuckerberg

Gil Press Contributor

Enterprise & Cloud

https://www.forbes.com/sites/gilpress/2019/01/08/the-ai-chronicles-combining-statistical-analysis-and-computing-from-hollerith-to-zuckerberg/#23cf507c73b3

 

Jan 2, 2015, 10:48am

A Very Short History Of The Internet And The Web

Gil Press Contributor

Enterprise & Cloud

https://www.forbes.com/sites/gilpress/2015/01/02/a-very-short-history-of-the-internet-and-the-web-2/#a45c9307a4e2

 

May 28, 2013, 09:09am

A Very Short History Of Data Science

Gil Press Contributor

Enterprise & Cloud

https://www.forbes.com/sites/gilpress/2013/05/28/a-very-short-history-of-data-science/#1e7db3e155cf

 

May 9, 2013, 09:45am

A Very Short History Of Big Data

Gil Press Contributor

Enterprise & Cloud

https://www.forbes.com/sites/gilpress/2013/05/09/a-very-short-history-of-big-data/#16c2043b65a1

 

Apr 8, 2013, 09:16am

A Very Short History of Information Technology (IT)

Gil Press Contributor

Enterprise & Cloud

https://www.forbes.com/sites/gilpress/2013/04/08/a-very-short-history-of-information-technology-it/#3f5491022440

 

A Pioneer Practitioner’s Portfolio of Algorithm-based Decision Support Systems for Operations Management in Several Industrial Verticals: Analytics Designer, Aviva Lev-Ari, PhD, RN

On this landscape about IT, The Internet, Analytics, Statistics, Big Data, Data Science and Artificial Intelligence, I am to tell stories on my own pioneering work in data science, Algorithm-based decision support systems design for different organizations in several sectors of the US economy:

  • Startups:
  1. TimeØ Group
  2. Concept Five Technologies, Inc.
  3. MDSS, Inc.
  4. LPBI Group
  • Top Tier Management Consulting: SRI International, Monitor Group;
  • OEM: Amdahl Corporation;
  • Top 6th System Integrator: Perot System Corporation;
  • FFRDC: MITRE Corporation.
  • Publishing industry: was Director of Research at McGraw-Hill/CTB.
  • Northeastern University, Researcher on Cardiovascular Pharmaco-therapy at Bouve College of Health Sciences (Independent research guided by Professor of Pharmacology)

Type of institutions:

  • For-Profit corporations: Amdahl Corp, PSC, McGraw-Hill
  • For-Profit Top Tier Consulting: Monitor Company, Now Deloitte
  • Not-for-Profit Top Tier Consulting: SRI International
  • FFRDC: MITRE
  • eScientific Publishing: LPBI Group: Developers of Curation methodology for e-Articles [N = 3,700], electronic Table of Contents for e-Books in Medicine [N = 16, https://lnkd.in/ekWGNqA] and e-Proceedings of Biotech Conferences [N = 70].

 

Autobiographical Annotations: Tribute to My Professors

 

Pioneering implementations of analytics to business decision making: contributions to domain knowledge conceptualization, research design, methodology development, data modeling and statistical data analysis: Aviva Lev-Ari, UCB, PhD’83; HUJI MA’76

https://pharmaceuticalintelligence.com/2018/05/28/pioneering-implementations-of-analytics-to-business-decision-making-contributions-to-domain-knowledge-conceptualization-research-design-methodology-development-data-modeling-and-statistical-data-a/

Recollections of Years at UC, Berkeley, Part 1 and Part 2

  • Recollections: Part 1 – My days at Berkeley, 9/1978 – 12/1983 – About my doctoral advisor, Allan Pred, other professors and other peers

https://pharmaceuticalintelligence.com/2018/03/15/recollections-my-days-at-berkeley-9-1978-12-1983-about-my-doctoral-advisor-allan-pred-other-professors-and-other-peer/

  • Recollections: Part 2 – “While Rolling” is preceded by “While Enrolling” Autobiographical Alumna Recollections of Berkeley – Aviva Lev-Ari, PhD’83

https://pharmaceuticalintelligence.com/2018/05/24/recollections-part-2-while-rolling-is-preceded-by-while-enrolling-autobiographical-alumna-recollections-of-berkeley-aviva-lev-ari-phd83/

Accomplishments

The Digital Age Gave Rise to New Definitions – New Benchmarks were born on the World Wide Web for the Intangible Asset of Firm’s Reputation: Pay a Premium for buying e-Reputation

For @AVIVA1950, Founder, LPBI Group @pharma_BI: Twitter Analytics [Engagement Rate, Link Clicks, Retweets, Likes, Replies] & Tweet Highlights [Tweets, Impressions, Profile Visits, Mentions, New Followers] https://analytics.twitter.com/user/AVIVA1950/tweets

Thriving at the Survival Calls during Careers in the Digital Age – An AGE like no Other, also known as, DIGITAL

Reflections on a Four-phase Career: Aviva Lev-Ari, PhD, RN, March 2018

Was prepared for publication in American Friends of the Hebrew University (AFHU), May 2018 Newsletter, Hebrew University’s HUJI Alumni Spotlight Section.

Aviva Lev-Ari’s profile was up on 5/3/2018 on AFHU website under the Alumni Spotlight at https://www.afhu.org/

On 5/11/2018, Excerpts were Published in AFHU e-news.

https://us10.campaign-archive.com/?u=5c25136c60d4dfc4d3bb36eee&id=757c5c3aae&e=d09d2b8d72

https://www.afhu.org/2018/05/03/aviva-lev-ari/

 

Read Full Post »


We would appreciate your participation in our survey, which will help us improve our ability to communicate medical and scientific content.

 

Please email the results of this survey to: avivalev-ari@alum.berkeley.edu

  • How do you generally get information about scientific and medical information and/or disease conditions?

Choose all that apply:

□ LPBI Group website

□ Scientific and medical web sites

□ Health reporting web sites

□ Medical trade publications

□ PubMed sites

□ Medical conferences and related web sites

□ Social media sites

□ Podcasts

□ Other _______________

  • When you visit the LPBI Group web site, which sections of the web site do you read?

□ Latest medical and scientific news coverage

□ Medical conference proceedings

□ Selection of 16 e-books

  • In general, do you think that the medical and scientific news coverage on the LPBI web site is too short or too long?

Choose one of the following answers:

□ Too short

□ Too long

□ Sufficient length

□ No opinion

  • How frequently do you visit the LPBI Group web  site?

□ 1-3 times per week

□ 1-3 times per  month

□ Less than once per month

  • When you read the information on the LPBI Group web site, how long are you typically on the site?

□ Less than 5 minutes

□ Less than 30 minutes

□ 60 minutes or more

  • Do you take advantage of the suggested links in the articles on the LPBI Group web site for additional related articles and resources?

□ I click on the text links in the articles I read

□ I click on the links at the ends of articles

If so, do you find this information relevant?

□ Yes

□ No

  • Please rate the quality of the LPBI Group web site, including medical and scientific news, medical conference proceedings and selection of e-books.
                                     
                                 Excellent    Good        Average        Poor           No Opinion
Content
Writing
Ease of reading
Stories of interest
Layout and design
  • Please indicate your agreement with this statement: LPBI Group strengthens my professional connection to current medical and scientific news and noteworthy topics of interest.

□ Strongly agree

□ Agree

□ Disagree

□ Strongly disagree

□ No Opinion

  • Please suggest overall comments about the value of the LPBI Group offerings (i.e., medical and scientific news coverage, medical conference proceedings, selection of e-books).

_____________________________________________________________________

_____________________________________________________________________

  • Please suggest overall comments about improvements to the LPBI Group web site.

______________________________________________________________________

  _____________________________________________________________________

  • What do you like most about the LPBI Group web site?

______________________________________________________________________

______________________________________________________________________­­­­­­­­­

  • What do you like least about the LPBI Group web site?

______________________________________________________________________

 _____________________________________________________________________

  • How did you arrive at this survey?

□ Found it on the LPBI Group web site

□ Found it on social media

□ Found it advertised in the LPBI Group web site

□ Word of mouth / a friend told me

□ LPBI email as I am a follower of this blog

□ Other (please specify)

  • Any suggestions for ways we can improve the LPBI Group web site, its medical and scientific news coverage, its medical conference coverage and selection of e-books?

______________________________________________________________________

______________________________________________________________________

Thank you for participating in our survey.

 

Please visit our LPBI Group of offerings:

For the LPBI Journal:

https://pharmaceuticalintelligence.com/

For the BioMed e-Series:

https://lnkd.in/ekWGNqA

For 70 Conference e-Proceedings:

https://pharmaceuticalintelligence.com/press-coverage/part-three-conference-eproceedings-deliverables-social-media-analytics/

                                                                        ###

Read Full Post »


Website Subscribers: Readership Survey for Leaders in Pharmaceutical Business Intelligence (LPBI) Group – PLEASE REPLY BY TAKING THE SURVEY

Survey Designer: Gail Thornton, PhD(c) 

 

We would appreciate your participation in our survey, which will help us improve our ability to communicate medical and scientific content.

 

Please email the results of this survey to: AvivaLev-Ari@alum.berkeley.edu

 

  1. How do you generally get information about scientific and medical information and/or disease conditions?

 

Choose all that apply:

 

□ LPBI Group website

□ Scientific and medical web sites

□ Health reporting web sites

□ Medical trade publications

□ PubMed sites

□ Medical conferences and related web sites

□ Social media sites

□ Podcasts

□ Other _______________

 

  1. When you visit the LPBI Group web site, which sections of the web site do you read?

□ Latest medical and scientific news coverage

□ Medical conference proceedings

□ Selection of 16 e-books

 

  1. In general, do you think that the medical and scientific news coverage on the LPBI web site is too short or too long?

 

Choose one of the following answers:

 

□ Too short

□ Too long

□ Sufficient length

□ No opinion

 

  1. How frequently do you visit the LPBI Group web site?

□ 1-3 times per week

□ 1-3 times per month

□ Less than once per month

 

  1. When you read the information on the LPBI Group web site, how long are you typically on the site?

□ Less than 5 minutes

□ Less than 30 minutes

□ 60 minutes or more

 

  1. Do you take advantage of the suggested links in the articles on the LPBI Group web site for additional related articles and resources?

 

□ I click on the text links in the articles I read

□ I click on the links at the ends of articles

 

If so, do you find this information relevant?

□ Yes

□ No

 

 

  1. Please rate the quality of the LPBI Group web site, including medical and scientific news, medical conference proceedings and selection of e-books.

 

                                   Excellent   Good        Average        Poor            No Opinion
Content
Writing
Ease of reading
Stories of interest
Layout and design

 

  1. Please indicate your agreement with this statement: LPBI Group strengthens my professional connection to current medical and scientific news and noteworthy topics of interest.

□ Strongly agree

□ Agree

□ Disagree

□ Strongly disagree

□ No Opinion

 

  1. Please suggest overall comments about the value of the LPBI Group offerings (i.e., medical and scientific news coverage, medical conference proceedings, selection of e-books).

 

_____________________________________________________________________

 

_____________________________________________________________________

 

  1. Please suggest overall comments about improvements to the LPBI Group web site.

 

______________________________________________________________________

 

______________________________________________________________________

 

 

  1. What do you like most about the LPBI Group web site?

 

______________________________________________________________________

 

______________________________________________________________________­­­­­­­­­

  1. What do you like least about the LPBI Group web site?

 

______________________________________________________________________

 

______________________________________________________________________

 

  1. How did you arrive at this survey?

□ Found it on the LPBI Group web site

□ Found it on social media

□ Found it advertised in the LPBI Group web site

□ Word of mouth / a friend told me

□ LPBI email as I am a follower of this blog

□ Other (please specify)

 

  1. Any suggestions for ways we can improve the LPBI Group web site, its medical and scientific news coverage, its medical conference coverage and selection of e-books?

 

______________________________________________________________________

 

______________________________________________________________________

 

 

 

Thank you for participating in our survey.

 

Please visit our LPBI Group of offerings:

 

  • For the LPBI Journal:

https://wordpress.com/view/pharmaceuticalintelligence.com

 

  • For the BioMed e-Series:

https://lnkd.in/ekWGNqA

 

  • For 70 Conference e-Proceedings:

https://pharmaceuticalintelligence.com/press-coverage/part-three-conference-eproceedings-deliverables-social-media-analytics/

 

###

 

 

 

 

Read Full Post »


We celebrated 5,700 Scientific Articles in @PharmaceuticalIntelligence.com on November 20, 2019

Editor-in-Chief: Aviva Lev-Ari, PhD, RN

 

5,700 Articles

691 Categories

10,128 Tags

 

1,688,036 e-Readers

7,369 comments

 

The Digital Age Gave Rise to New Definitions – New Benchmarks were born on the World Wide Web for the Intangible Asset of Firm’s Reputation: Pay a Premium for buying e-Reputation

 

For the Journal Access:

https://wordpress.com/view/pharmaceuticalintelligence.com

For the BioMed e-Series Access:

https://wordpress.com/view/pharmaceuticalintelligence.com

For 70 Conference e-Proceedings Access:

https://pharmaceuticalintelligence.com/press-coverage/part-three-conference-eproceedings-deliverables-social-media-analytics/

 

Other links may be of interest:

  1. Executive Summary
  2. Opportunities Map in the Acquisition Arena
  3. Dynamic Contents for LPBI Group’s PowerPoint Presentation
  4. Detailed Technology Description
  5. Curation Methodology – Digital Communication Technology to mitigate Published Information Explosion and Obsolescence in Medicine and Life Sciences
  6. Top Authors by Number of eReaders Views
  7. Top Articles by Number of e-Readers for All Days ending 2019-02-17
  8. LPBI Group’s Social Media Presence
  9. Financial Valuation of Three Health Care Intellectual Property (IP) Content Asset Classes
  10. Global Market Penetration Forecast for each Volume in the 16 Volume BioMed e-Series
  11. Potential Use of LPBI IP as Value Price Driver by Potential Acquirer: Assumptions per Asset Class 
  12. Financial Advisory & Legal Advisory Providers: US & Israel
  13. Founder’s Role in the Development of Venture’s Factors of Content Production – Biographical Notes by Aviva Lev-Ari, PhD, RN, LPBI Group
  14. FIT Members Contribute to Opportunities Map
  15. FINAL IMPROVEMENT TEAM (FIT): Definition of Active, Lapsing of Active Status, COMPs Formulas
  16. Mostly HONORED to be followed by [from an Excerpt of 117 Followers of the Twitter Account @AVIVA1950 from the List of 359 Followers] by the Number of their Followers on 2/24/2019
  17. LPBI Group is mostly HONORED to be followed by [from an Excerpt of 136 Followers of the Twitter Account @pharma_BI from the List of 505 Followers] by the Number of their Followers on 3/20/2019
  18. FIT members – Who works on WHAT?
  19. Comparative Analysis of the Level of Engagement for Four Twitter Accounts: @KDNuggets (Big Data) @GilPress @Forbes @pharma_BI @AVIVA1950
  20. MEDIA organizations as Followers of @pharma_BI the Official Twitter Account of LPBI Group (136 out of 505 Followers): Number of Followers’ Followers, Institutions (I) and Individuals (Persons(P)), RED = Mostly Honored to be followed by
  21. JOURNAL Statistics on 2/24/2019
  22. Excerpt of 136 Followers of @pharma_BI (from the List of 505 Followers) by the Number of their Followers on 3/20/2019
  23. Excerpt of 117 Followers of @AVIVA1950 (from the List of 359 Followers) by the Number of their Followers
  24. REACH – Two Handles on Twitter.com @AVIVA1950 @pharma_BI
  25. 2013-2019, On the Medical & Scientific Bookshelf in Kindle Store: eReader Behaviors: Browsing, Page Downloads and Buying e-Books – LPBI Group’s BioMed e-Series, Royalties Payment Analysis 
  26. Connections First Level on LinkedIn: 500 CEOs, 200 Big Pharma Professionals, 7,000 in Total: LPBI Group Founder – Aviva Lev-Ari, PhD, RN
  27. Summer 2019 Plan – Research Associates Tasks
  28. LPBI’s Pipeline Map: A Positioning Perspectives – An Outlook to the Future from the Present
  29. WHAT ARE LPBI Group’s NEEDS in June 2019: Aviva’s BOLD VISION on June 11, 2019
  30. For @AVIVA1950, Founder, LPBI Group @pharma_BI: Twitter Analytics [Engagement Rate, Link Clicks, Retweets, Likes, Replies] & Tweet Highlights [Tweets, Impressions, Profile Visits, Mentions, New Followers] https://analytics.twitter.com/user/AVIVA1950/tweets

Read Full Post »


Tweets and Retweets by @AVIVA1950 and by @pharma_BI for 15th Annual Personalized Medicine Conference at Harvard Medical School – THE PARADIGM EVOLVES, November 13 – 14, 2019 • Harvard Medical School, Boston, MA

Real Time Press Coverage: Aviva Lev-Ari, PhD, RN

see also,

eProceedings 15th Annual Personalized Medicine Conference at Harvard Medical School – THE PARADIGM EVOLVES, November 13 – 14, 2019 • Harvard Medical School, Boston, MA

https://pharmaceuticalintelligence.com/2019/07/19/15th-annual-personalized-medicine-conference-at-harvard-medical-school-the-paradigm-evolves-november-13-14-2019-%e2%80%a2-harvard-medical-school-boston-ma/

 

 

Tweets by @AVIVA1950 and by @pharma_BI

Aviva Lev-Ari
@AVIVA1950

#PMConf

Donald L. Siegel, Ph.D., M.D., Director, Division of Transfusion Medicine & Therapeutic Biology, Director, Clinical Cell and Vaccine Production Facility, UPenn’s Perelman School of Medicine no relations explored between Immune T cells and microbiome

2
1

Aviva Lev-Ari
@AVIVA1950

#PMConf

Paul Stoffels, M.D., Vice Chairman, Executive Committee, Chief Scientific Officer, Johnson & Johnson Impact of Mirobiome it plays a key role in many diseases difficult to develop therapeutics derived from microbiome data

1
1

Aviva Lev-Ari
@AVIVA1950

#PMConf

Harpreet Singh, Ph.D., CEO, Immatics T Cell peptide started 15 years ago Peptonomics,  tumors of solid cancer – cell therapies selected from libraries  off the shelf cells from health donors Biologics bridges tumor cells and solid cells

1

Aviva Lev-Ari
@AVIVA1950

#PMConf

Donald L. Siegel, Ph.D., M.D., Director, Division of Transfusion Medicine & Therapeutic Biology, Director, Clinical Cell and Vaccine Production Facility, UPenn’s Medicine CAR-T therapy started the Transfusion Medicine & Therapeutic Biology industry

Aviva Lev-Ari
@AVIVA1950

#PMConf

Paul Stoffels, M.D., Vice Chairman, Executive Committee, Chief Scientific Officer, Johnson & Johnson Combination therapy emerges, MOA partnerships: cell therapy can transform cancer treatment INFECTIOUS disease had Global impact need stop the virus

Aviva Lev-Ari
@AVIVA1950

#PMConf

Paul Stoffels, M.D., #CSO

Platforms are established, every 20-30 another one emergences access to data – critical platform AI for diagnostics and decision making biomarkers J&J try to learn on every disease: Lungs and GI Diagnosis HIV Vaccine

Aviva Lev-Ari
@AVIVA1950

#PMConf

Paul Stoffels, M.D., Vice Chairman, Executive Committee, Chief Scientific Officer, Johnson & Johnson Goals of medicine in 2019 early detection Vaccines in disease prevention Longevity

Aviva Lev-Ari
@AVIVA1950

#PMConf

Joseph B. Martin, M.D., Ph.D., Dean Emeritus

fascinating personal history story on development of interest in genetic analysis

Aviva Lev-Ari
@AVIVA1950

#PMConf

Michael J. Pellini, MD Diagnostics Pain management  Patients can fight more broadly F for sharing data and data exchange 80% patients do not access Academic Centers for treatment

Aviva Lev-Ari
@AVIVA1950

#PMConf

Michael J. Pellini, MD surgery, chemo, radiation – cost, harmful, INEFFECTIVE, Dr. Reza Columbia Medical School Oncologist 35 years How are we doing with technology? Very remarkable Clinical Utility to the Payer Regulatory – a super star in ten years

Aviva Lev-Ari
@AVIVA1950

#PMConf

Stephen L. Eck, Carl June, UPenn Beyond Cancer: Chronic diseases have systemic of specific immune or autoimmune components: CNS, neurodegenerative and Diabetes, Sickle cell anemia – treatment by cell therapy microphages

Aviva Lev-Ari
@AVIVA1950

#PMConf

Stephen L. Eck, Carl June, UPenn Cost of cell transfection therapy: Cost of Goods, Cost of Labor – pay for performance,  Manufacture in NJ shipped to Europe – not effective

Aviva Lev-Ari
@AVIVA1950

#PMConf

Stephen L. Eck, Carl June, UPenn Similarity between Transfusion Medicine industry and Cell therapy – Transfection of cells therapy  Manufacturing of Cells for transfection: Over regulation like in small molecules vs too little regulation

Aviva Lev-Ari
@AVIVA1950

#PMConf

Stephen L. Eck, Carl June, UPenn engineering T cells life farming – innovation is the driver, FDA is evolving in handling patents involved in Cell engineering Regulatory science needs to evolve in light of gene therapy in Human cell line in China

Aviva Lev-Ari
@AVIVA1950

#PMConf

Stephen L. Eck, Carl June, UPenn Children vs Adults 2011 reported better results in Adults, children’s immune system is evolving  In 2019 – 13 biotech companies in CAR-T cell therapies, Gene therapy is growing FDA, drug cycle T cells vs stem cells

Aviva Lev-Ari
@AVIVA1950

#PMConf

15th Annual meeting is at a historic moment in Boston where Prof. Church launched the Human Genome Project and Eric Launder at MIT and the Cancer Genome Project. Genzyme conceived gene therapy sold to Sanofi for $ Billion  Foundation Medicine

1

Aviva Lev-Ari
@AVIVA1950

#PMConf

Edward Abrahams, Ph.D., President, PMC 170 drugs with biomarkers, up 15% from 2000 in Biomarker strategy Gene therapy started in 2005, today personalized medicine is becoming standard of care. Science & Technology need additional friendly environment

1

Aviva Lev-Ari
@AVIVA1950

#PMConf

Kenna R. Mills Shaw, Ph.D., MD Anderson Institute does not sequence genome of each patient unlike Dana Farber clinicians need to access information for decision making when disease progresses – what new test to order data sharing inside the institute

Aviva Lev-Ari
@AVIVA1950

#PMConf

Daryl Pritchard, Ph.D., Senior Vice President, Science Policy, PMC Genomic sequencing for a single test that covers many biomarkers Improve treatment efficiency Growing recognition of the need to demonstrate value, evidence for Payers to pay

1

Aviva Lev-Ari
@AVIVA1950

#PMConf

Ammar Qadan, Vice President, Global Head of Market Access, Illumina Illumina is building evidence for Harvard Pilgrim on theirs patient data on risk pregnancies Illumina is expanding  building evidence for ALL rare diseases for all Test diagnostics

Aviva Lev-Ari
@AVIVA1950

#PMConf

Roy J. Gandolfi, M.D., Medical Director, SelectHealth, UT is the Payer of Intermountain Healthcare, UT Regional approach vs National perspective medical policies requires experts for Payer to approve a treatment Consumer in the health plan

Aviva Lev-Ari
@AVIVA1950

#PMConf

Lincoln Nadauld, M.D., Ph.D., Chief, Precision Health, Intermountain Healthcare, UT Precision Oncology Program: Need, study, analysis outcome, publish dataPharmacogenetics testing will be covered for all employees & Neonatal

Aviva Lev-Ari
@AVIVA1950

#PMConf

Peter J. Neumann, Sc.D., Tufts Medical Center clinical utility evidence of value: saving by diagnostics cost for quality cost of diagnostics cost effectiveness – characterize utility cost effectiveness – study Value to families value of knowledge

Aviva Lev-Ari
@AVIVA1950

#PMConf

Ammar Qadan, Vice President, Global Head of Market Access, Illumina Illumina is partnering with providers and Payer Illumina & Blue Cross Blue Shield 150 Million are covered for genomics 2500 genomics test done Under utilization educate physician

Aviva Lev-Ari
@AVIVA1950

#PMConf

Mark P. Stevenson, COO Thermo Fisher Scientific Context: Therapy selection in personalized medicine navigate diagnostics in use and policies when implementations is considered Physicians need precise testing now Payers evidence of utility is needed

1

Aviva Lev-Ari
@AVIVA1950

#PMConf

Mark P. Stevenson, Executive Vice President, Chief Operating Officer, Thermo Fisher Scientific Patient Outcome – Data analytics, ML, AI for genomics, proteomics, metabolomics, Tests must be precise and inform the diagnosis by diagnostics Solutions

Aviva Lev-Ari
@AVIVA1950

#PMConf

Paul Stoffels, M.D., Vice Chairman, Executive Committee, Chief Scientific Officer, Johnson & Johnson Passion of Scientists pharmaceutics development is based on insights looking into the future – important goal to solve

Aviva Lev-Ari
@AVIVA1950

#PMConf

best conference on Personalized Medicine in 15 years eProceedings 15th Annual Personalized Medicine Conference at Harvard Medical School – THE PARADIGM EVOLVES, November 13 – 14, 2019 • Harvard Medical School, Boston, MA

eProceedings 15th Annual Personalized Medicine Conference at Harvard Medical School – THE PARADIGM…
eProceedings 15th Annual Personalized Medicine Conference at Harvard Medical School – THE PARADIGM EVOLVES, November 13 – 14, 2019 • Harvard Medical School, Boston, MA   The 15th Annual …
pharmaceuticalintelligence.com

Aviva Lev-Ari
@AVIVA1950

Your synopsis of the best Personalized Medicine Conference organized to date #PMConf

Quote Tweet
Aviva Lev-Ari
@AVIVA1950
·
#PMConf @pharma_BI @AVIVA1950 best conference on Personalized Medicine in 15 years eProceedings 15th Annual Personalized Medicine Conference at Harvard Medical School – THE PARADIGM EVOLVES, November 13 – 14, 2019 • Harvard Medical School, Boston, MA pharmaceuticalintelligence.com/2019/07/19/15t

 Retweet by @AVIVA1950

Aviva Lev-Ari
@AVIVA1950

A true leader in Pharmaceutical domain, also Member of the National Academy of Art and Sciences #PMConf

Quote Tweet
Cynthia Bens
@bens_cynthia
·
Introducing the amazing @ScottGottliebMD was a highlight of #pmconf. His vision for balanced regulatory and coverage policies is desperately needed now to support the future of #personalizedmedicine @permedcoalition

Image

Aviva Lev-Ari
@AVIVA1950

#PMConf

Best Case study

Quote Tweet
PMC
@permedcoalition
·
This year’s #PMConf case study on the @TheDDFund puts a spotlight on what one can do to combine modern entrepreneurial finance approaches to tackle a very complex problem such as Alzheimer’s Disease. @RHamermesh @HarvardHBS #PMConf

Image

Aviva Lev-Ari
@AVIVA1950

#PMConf

Edward Abrahams, Ph.D., President, PMC 170 drugs with biomarkers, up 15% from 2000 in Biomarker strategy Gene therapy started in 2005, today personalized medicine is becoming standard of care. Science & Technology need additional friendly environment

1

Genomic Health®
@GenomicHealth

We’re proud to announce Steve Shak is the recipient of the Leadership in Personalized Medicine Award at the 15th Annual Personalized Medicine Conference: The Paradigm Evolves. Please come and see him speak at the conference. bit.ly/2lMAteZ #PMConf

Image

1
7

Read Full Post »

Older Posts »